At the IGTP TODAY

News

- Campus Can Ruti, Research

Screening high-risk groups for tuberculosis in low-incidence countries: a cost-effective strategy

A study led by researchers from IGTP, in collaboration with health economics experts from Can Ruti, UPF, and Agència de Salut Pública de Barcelona, offers new recommendations for optimising tuberculosis screening programmes in low-incidence countries. Published in the journal Eurosurveillance, this work reviews various studies to determine if these programmes targeting higher-risk groups are economically effective.

- Innovation, Projects, Research

The new clinical trial CONSTAN testing of effectiveness of the RUTI® vaccine to shorten tuberculosis treatment times

The biotechnology company Archivel Farma has designed and set up a phase IIb clinical study called CONSTAN to explore whether administering the immunotherapy RUTI®, known as the RUTI® vaccine, along with the standard treatment for patients with pulmonary tuberculosis (TB) improves results. The principal investigator of the project is Dr Cristina Vilaplana, leader of the Experimental Tuberculosis Unit (UTE) at the Germans Trias I Pujol Research Institute (IGTP). The study has been approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) and the First Patient In will be welcomed in January 2022